Enhanced hypoxia resistance distinguishes human pluripotent stem cell-derived islets from primary islets
American Journal of Physiology-Cell Physiology · 2026
DOI: 10.1152/ajpcell.00043.2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2026. Verfasst von Hiroyuki Kato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplant Surgery, Department of Surgery, University of California, San Francisco, California, United States. Hauptthemen laut MEDLINE: Islets of Langerhans, Oxygen, Pluripotent Stem Cells, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Breakthrough T1D (JDF), Nora Eccles Treadwell Foundation.
Abstract (Originalsprache)
This study provides the first quantitative evidence that human stem cell-derived islets are more resistant to hypoxia than primary human islets. Stem cell-derived islets maintain viability at substantially lower oxygen levels and exhibit markedly reduced variability in hypoxia tolerance. These findings identify hypoxia resistance as a key functional advantage of stem cell-derived islets, with important implications for transplantation into low-oxygen environments and for scalable islet fabrication strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Transplant Surgery, Department of Surgery, University of California, San Francisco, California, United States.
- Department of Medical Engineering, California Institute of Technology, Pasadena, California, United States.
- Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute of City of Hope, Duarte, California, United States.
- Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
ORCID-Profile: Hiroyuki Kato, Kuang-Ming Shang, Hiroaki Mitsugashira, Peter G Stock, Taro Toyoda, Hirotake Komatsu
Förderung
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Breakthrough T1D (JDF)
- Nora Eccles Treadwell Foundation
- NIDDK NIH HHS
Zitieren
APA
Kato, H., Shang, K. M., Mitsugashira, H., Qi, M., Suzuki, T., Stock, P. G., Toyoda, T., Tai, Y. C., Kandeel, F., & Komatsu, H. (2026). Enhanced hypoxia resistance distinguishes human pluripotent stem cell-derived islets from primary islets. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00043.2026
Vancouver
Kato H, Shang KM, Mitsugashira H, Qi M, Suzuki T, Stock PG, et al. Enhanced hypoxia resistance distinguishes human pluripotent stem cell-derived islets from primary islets. American Journal of Physiology-Cell Physiology. 2026. doi:10.1152/ajpcell.00043.2026
BibTeX
@article{Kato2026,
author = {Kato, Hiroyuki and Shang, Kuang-Ming and Mitsugashira, Hiroaki and Qi, Meirigeng and Suzuki, Tomoharu and Stock, Peter G and Toyoda, Taro and Tai, Yu-Chong and Kandeel, Fouad and Komatsu, Hirotake},
title = {Enhanced hypoxia resistance distinguishes human pluripotent stem cell-derived islets from primary islets},
journal = {American Journal of Physiology-Cell Physiology},
year = {2026},
doi = {10.1152/ajpcell.00043.2026}
}
EUVIMED